Schilling T, Pecherstorfer M, Blind E, Kohl B, Wagner H, Ziegler R, Raue F
Department of Internal Medicine I, University of Heidelberg, Germany.
Bone. 1996 Apr;18(4):315-9. doi: 10.1016/8756-3282(96)00002-6.
In 50-90% of cases, humoral hypercalcemia of malignancy (HHM) is due to tumor secretion of parathyroid hormone-related protein (PTHrP). Glucocorticoids are sometimes used as calcium lowering agents and there are in vitro results showing that glucocorticoids diminish PTHrP production. In this study we tested whether the serum-calcium-lowering effect of glucocorticoids is due to decreased PTHrP production by the tumor. As an animal and cell culture model we used the Walker carcinosarcoma (WCS) 256, a rat mammary carcinoma cell line producing PTHrP. In vitro, dexamethasone caused a dose-dependent inhibition of PTHrP production, whereby already 1-5 nmol/L revealed a significant decrease by WCS 256 cells. In contrast to these in vitro results, in WCS 256 tumor-bearing rats, dexamethasone (4 mg/kg body weight on day 4, and 1 mg/kg body weight from day 5 until day 7 after WCS transplantation; circulating dexamethasone levels > 20 nmol/L) did not decrease PTHrP production, PTHrP secretion, serum calcium, or tumor weight in vivo. We conclude that, in this PTHrP-mediated model of humoral hypercalcemia of malignancy, glucocorticoids do not decrease PTHrP production and secretion in vivo and do not show a calcium-lowering effect.
在50%-90%的病例中,恶性肿瘤体液性高钙血症(HHM)是由肿瘤分泌甲状旁腺激素相关蛋白(PTHrP)所致。糖皮质激素有时被用作降钙药物,并且有体外实验结果表明糖皮质激素可减少PTHrP的产生。在本研究中,我们测试了糖皮质激素降低血清钙的作用是否归因于肿瘤PTHrP产生的减少。我们使用Walker癌肉瘤(WCS)256(一种产生PTHrP的大鼠乳腺癌细胞系)作为动物和细胞培养模型。在体外,地塞米松引起PTHrP产生的剂量依赖性抑制,其中1-5 nmol/L的地塞米松即可使WCS 256细胞产生的PTHrP显著减少。与这些体外实验结果相反,在荷WCS 256肿瘤的大鼠中,地塞米松(在WCS移植后第4天给予4 mg/kg体重,从第5天至第7天给予1 mg/kg体重;循环中的地塞米松水平>20 nmol/L)在体内并未减少PTHrP的产生、PTHrP的分泌、血清钙或肿瘤重量。我们得出结论,在这种由PTHrP介导的恶性肿瘤体液性高钙血症模型中,糖皮质激素在体内并未减少PTHrP的产生和分泌,也未显示出降钙作用。